Using Extracellular Vesicles Released by GDNF-Transfected Macrophages for Therapy of Parkinson Disease

Overview

Journal Cells

Publisher MDPI

Specialties Biochemistry
Biophysics
Cell Biology
Molecular Biology

Date 2022 Jun 24

PMID 35741061

Authors

Yuling Zhao

Matthew J Haney

John K Fallon

Myosotys Rodriguez

Carson J Swain

Camryn J Arzt

Philip C Smith

Matthew Shane Loop

Emily B Harrison

Nazira El-Hage

Elena V Batrakova

Affiliations

Soon will be listed here.

Abstract

Extracellular vesicles (EVs) are cell-derived nanoparticles that facilitate transport of proteins, lipids, and genetic material, playing important roles in intracellular communication. They have remarkable potential as non-toxic and non-immunogenic nanocarriers for drug delivery to unreachable organs and tissues, in particular, the central nervous system (CNS). Herein, we developed a novel platform based on macrophage-derived EVs to treat Parkinson disease (PD). Specifically, we evaluated the therapeutic potential of EVs secreted by autologous macrophages that were transfected ex vivo to express glial-cell-line-derived neurotrophic factor (GDNF). EV-GDNF were collected from conditioned media of GDNF-transfected macrophages and characterized for GDNF content, size, charge, and expression of EV-specific proteins. The data revealed that, along with the encoded neurotrophic factor, EVs released by pre-transfected macrophages carry GDNF-encoding DNA. Four-month-old transgenic Parkin Q311(X)A mice were treated with EV-GDNF via intranasal administration, and the effect of this therapeutic intervention on locomotor functions was assessed over a year. Significant improvements in mobility, increases in neuronal survival, and decreases in neuroinflammation were found in PD mice treated with EV-GDNF. No offsite toxicity caused by EV-GDNF administration was detected. Overall, an EV-based approach can provide a versatile and potent therapeutic intervention for PD.

Citing Articles

Cationized extracellular vesicles for gene delivery.

Klyachko N, Haney M, Lopukhov A, Le-Deygen I Sci Rep. 2024; 14(1):25818.

PMID: 39468145 PMC: 11519934. DOI: 10.1038/s41598-024-75985-y.

An Overview on the Physiopathology of the Blood-Brain Barrier and the Lipid-Based Nanocarriers for Central Nervous System Delivery.

Susa F, Arpicco S, Pirri C, Limongi T Pharmaceutics. 2024; 16(7).

PMID: 39065547 PMC: 11279990. DOI: 10.3390/pharmaceutics16070849.

Extracellular vesicles as nanotheranostic platforms for targeted neurological disorder interventions.

Choi H, Chen M, Goldston L, Lee K Nano Converg. 2024; 11(1):19.

PMID: 38739358 PMC: 11091041. DOI: 10.1186/s40580-024-00426-5.

Immune cells: potential carriers or agents for drug delivery to the central nervous system.

Zhang S, Li R, Chen Z, Wang X, Dumont A, Fan X Mil Med Res. 2024; 11(1):19.

PMID: 38549161 PMC: 10979586. DOI: 10.1186/s40779-024-00521-y.

Endogenous GDNF Is Unable to Halt Dopaminergic Injury Triggered by Microglial Activation.

Mendes-Oliveira J, Campos F, Ferreira S, Tome D, Fonseca C, Baltazar G Cells. 2024; 13(1).

PMID: 38201277 PMC: 10778367. DOI: 10.3390/cells13010074.

References

Khatri R, Fallon J, Rementer R, Kulick N, Lee C, Smith P . Targeted quantitative proteomic analysis of drug metabolizing enzymes and transporters by nano LC-MS/MS in the sandwich cultured human hepatocyte model. J Pharmacol Toxicol Methods. 2019; 98:106590. PMC: 6701468. DOI: 10.1016/j.vascn.2019.106590. View

Haney M, Zhao Y, Jin Y, Batrakova E . Extracellular Vesicles as Drug Carriers for Enzyme Replacement Therapy to Treat CLN2 Batten Disease: Optimization of Drug Administration Routes. Cells. 2020; 9(5). PMC: 7290714. DOI: 10.3390/cells9051273. View

Dou H, Destache C, Morehead J, Mosley R, Boska M, Kingsley J . Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery. Blood. 2006; 108(8):2827-35. PMC: 1895582. DOI: 10.1182/blood-2006-03-012534. View

Haney M, Klyachko N, Harrison E, Zhao Y, Kabanov A, Batrakova E . TPP1 Delivery to Lysosomes with Extracellular Vesicles and their Enhanced Brain Distribution in the Animal Model of Batten Disease. Adv Healthc Mater. 2019; 8(11):e1801271. PMC: 6584948. DOI: 10.1002/adhm.201801271. View

Kim M, Haney M, Zhao Y, Yuan D, Deygen I, Klyachko N . Engineering macrophage-derived exosomes for targeted paclitaxel delivery to pulmonary metastases: in vitro and in vivo evaluations. Nanomedicine. 2017; 14(1):195-204. DOI: 10.1016/j.nano.2017.09.011. View

Chen C, Liu L, Ma F, Wong C, Guo X, Chacko J . Elucidation of Exosome Migration across the Blood-Brain Barrier Model In Vitro. Cell Mol Bioeng. 2017; 9(4):509-529. PMC: 5382965. DOI: 10.1007/s12195-016-0458-3. View

Hemler M . Tetraspanin proteins mediate cellular penetration, invasion, and fusion events and define a novel type of membrane microdomain. Annu Rev Cell Dev Biol. 2003; 19:397-422. DOI: 10.1146/annurev.cellbio.19.111301.153609. View

Whone A, Luz M, Boca M, Woolley M, Mooney L, Dharia S . Randomized trial of intermittent intraputamenal glial cell line-derived neurotrophic factor in Parkinson's disease. Brain. 2019; 142(3):512-525. PMC: 6391602. DOI: 10.1093/brain/awz023. View

Kameda M, Shingo T, Takahashi K, Muraoka K, Kurozumi K, Yasuhara T . Adult neural stem and progenitor cells modified to secrete GDNF can protect, migrate and integrate after intracerebral transplantation in rats with transient forebrain ischemia. Eur J Neurosci. 2007; 26(6):1462-78. DOI: 10.1111/j.1460-9568.2007.05776.x. View

10.

Fallon J, Neubert H, Hyland R, Goosen T, Smith P . Targeted quantitative proteomics for the analysis of 14 UGT1As and -2Bs in human liver using NanoUPLC-MS/MS with selected reaction monitoring. J Proteome Res. 2013; 12(10):4402-13. DOI: 10.1021/pr4004213. View

11.

Yuan D, Zhao Y, Banks W, Bullock K, Haney M, Batrakova E . Macrophage exosomes as natural nanocarriers for protein delivery to inflamed brain. Biomaterials. 2017; 142:1-12. PMC: 5603188. DOI: 10.1016/j.biomaterials.2017.07.011. View

12.

Eketjall S, Fainzilber M, Ibanez C . Distinct structural elements in GDNF mediate binding to GFRalpha1 and activation of the GFRalpha1-c-Ret receptor complex. EMBO J. 1999; 18(21):5901-10. PMC: 1171656. DOI: 10.1093/emboj/18.21.5901. View

13.

Haney M, Klyachko N, Zhao Y, Gupta R, Plotnikova E, He Z . Exosomes as drug delivery vehicles for Parkinson's disease therapy. J Control Release. 2015; 207:18-30. PMC: 4430381. DOI: 10.1016/j.jconrel.2015.03.033. View

14.

Suzuki M, McHugh J, Tork C, Shelley B, Klein S, Aebischer P . GDNF secreting human neural progenitor cells protect dying motor neurons, but not their projection to muscle, in a rat model of familial ALS. PLoS One. 2007; 2(8):e689. PMC: 1925150. DOI: 10.1371/journal.pone.0000689. View

15.

Mignot G, Roux S, Thery C, Segura E, Zitvogel L . Prospects for exosomes in immunotherapy of cancer. J Cell Mol Med. 2006; 10(2):376-88. PMC: 3933128. DOI: 10.1111/j.1582-4934.2006.tb00406.x. View

16.

Tsuji , Tamai I . Carrier-mediated or specialized transport of drugs across the blood-brain barrier. Adv Drug Deliv Rev. 2000; 36(2-3):277-290. DOI: 10.1016/s0169-409x(98)00084-2. View

17.

Bagno L, Hatzistergos K, Balkan W, Hare J . Mesenchymal Stem Cell-Based Therapy for Cardiovascular Disease: Progress and Challenges. Mol Ther. 2018; 26(7):1610-1623. PMC: 6037203. DOI: 10.1016/j.ymthe.2018.05.009. View

18.

Batchelor P, Liberatore G, Wong J, Porritt M, Frerichs F, Donnan G . Activated macrophages and microglia induce dopaminergic sprouting in the injured striatum and express brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor. J Neurosci. 1999; 19(5):1708-16. PMC: 6782182. View

19.

Haney M, Suresh P, Zhao Y, Kanmogne G, Kadiu I, Sokolsky-Papkov M . Blood-borne macrophage-neural cell interactions hitchhike on endosome networks for cell-based nanozyme brain delivery. Nanomedicine (Lond). 2012; 7(6):815-33. PMC: 3384770. DOI: 10.2217/nnm.11.156. View

20.

Braak H, Del Tredici K, Rub U, de Vos R, Jansen Steur E, Braak E . Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. 2002; 24(2):197-211. DOI: 10.1016/s0197-4580(02)00065-9. View